Introduction
============

Non-invasive ventilation (NIV) has become the modality of choice to treat mild to moderate respiratory acidosis (pH ≥7.20) due to chronic obstructive pulmonary disease (COPD) exacerbation, since it has been shown to avoid intubation and intubation-related complications, resulting in reduced ICU-mortality \[[@B1]\]. However, real-life observations have revealed high rates of both intubation and mortality in patients with COPD exacerbation and severe acute hypercapnic respiratory failure \[[@B2]-[@B4]\]. This is related to severe respiratory acidosis, well-established contraindications of NIV, lack of staff training and the presence of co-morbidities hindering the successful application of NIV \[[@B5],[@B6]\].

This has led to the attempt of extracorporeal carbon dioxide (CO~2~) removal (ECCO~2~R) in patients presenting with acute hypercapnic respiratory failure. ECCO~2~R systems have been successfully used to reduce invasiveness of mechanical ventilation and, therefore, ventilator-induced lung injury in acute respiratory distress syndrome (ARDS) patients \[[@B7]-[@B12]\]. Recently, ECCO~2~R by means of a pumpless, arterio-venous extracorporeal lung-assist has been shown to preclude the need for intubation and invasive mechanical ventilation in a case--control study in COPD patients with acute-on-chronic respiratory failure \[[@B13]\]. In addition, previous research has demonstrated that this technique is capable of eliminating approximately 50% of the calculated CO~2~ production, with rapid normalization of respiratory acidosis \[[@B14]\]. Importantly, these systems are driven by the arterio-venous pressure gradient; thus, cannulation of arterial vessels (most commonly the femoral artery), coupled with cannulation of the corresponding vein on the contralateral limb, is necessary for driving the system \[[@B13]-[@B15]\]. Based on these preconditions, there are clearly defined contraindications and several complications directly related to arterial cannulation, such as bleeding, hematoma or aneurysm at the insertion site, and ischemia and/or compartment syndrome of the lower limb \[[@B15],[@B16]\].

Interestingly, a recent study reported the successful application of a pump-driven veno-venous system using a 15.5 French (Fr) dual-lumen catheter with a mean blood flow of 431 ml/minute \[[@B17]\]. Even though this was a pilot study testing the feasibility of this new approach, the study showed the potential of these veno-venous systems to improve respiratory acidosis without requiring arterial cannulation. However, patients only had moderate respiratory acidosis, and it remains unclear how these results translate to more severe respiratory acidosis. Accordingly, clinical experience suggests that substantially higher flow rates are needed to correct severe respiratory acidosis (pH \<7.2) \[[@B18]\]. In this regard, the physiological relationships between cannula size, blood flow, sweep gas flow and gas transfer capacity, respectively, are still largely unknown. For this reason, more physiological data on these issues are needed before the promising technique of miniaturized veno-venous ECCO~2~R can be tested in a broader clinical setting. Therefore, we set up an animal study that aimed to elucidate the relationships between cannula size, blood flow and sweep gas flow, respectively, in pigs with experimentally-induced severe respiratory acidosis that mimicked severe acute hypercapnic respiratory failure with pH values between 7.0 and 7.2.

Material and methods
====================

Extracorporeal CO~2~ removal techniques
---------------------------------------

For ECCO~2~R a pump assisted lung protection (PALP) System® (Maquet Cardiopulmonary Care, Rastatt, Germany) based on the Cardiohelp® platform was used. The oxygenator has an area of 0.98 m^2^ with a poly methylpentene membrane lacking heat exchange fibers. The priming volume of the whole system is 247 ml. The PALP system® was primed with normal saline solution. Heparin (1,000 IE) was added to the running system.

For venous access, a 14.5Fr hemodialysis catheter (Fresenius Medical Care, Bad Homburg Germany) was used during Experiments 1 and 2, while a 19Fr Bicaval Avalon ELITE Dual Lumen Cannula® (Maquet Cardiopulmonary Care, Rastatt, Germany) was implanted for Experiments 3, 4 and 5. Pigs were anticoagulated with heparin during extracorporeal treatment. For all experiments, the sweep gas flow was applied with 100% oxygen by a Flow-i Anesthesia Delivery System (Maquet Critical Care, Solna, Sweden); in a subset of animals the sweep gas flow was provided with room air.

Animal model
------------

The study was approved by the Animal Research Committee of Uppsala University in Sweden (ethical approval number: C265/12). Pigs (body weight = 39.8 ± 2.9 kg) were anesthetized with IV ketamine 25 to 50 mg/kg/hour, midazolam 90 to 180 μg/kg/hour, fentanyl 3 to 6 μg/kg/hour and rocuronium 2.5 to 5.0 mg/kg/hour. The trachea was intubated with a cuffed endotracheal tube (inner diameter, 7 mm). The pigs were ventilated with a Servo-i ventilator (Maquet Critical Care, Solna, Sweden). Body temperature was kept at 37°C throughout the whole study period by the use of a warm blanket. Arterial blood was taken from the left carotid artery. The estimated CO~2~ production is about 7 ml/kg/minute in pigs \[[@B19]\], that is, a CO~2~ production of approximately 280 ml/minute, which is comparable to an adult human.

Study design
------------

ECCO~2~R was performed in six pigs following intubation, mechanical ventilation and induction of respiratory acidosis by increased dead space ventilation. In detail, anatomical dead space was increased by adding a further tube between the endotracheal tube and the 'Y' piece of the ventilator circuit. The length of the additional tube was titrated until respiratory acidosis was induced with a pH value of 7.0 to 7.1. Pigs were ventilated in a volume controlled mode with a tidal volume of 360 ml, a positive end expiratory pressure (PEEP) of 6 cm H~2~O and a breathing frequency of 15/minute. Dead space fractions and CO~2~ elimination were measured with a NICO monitor (Philips, Wallingford, CT, USA), where airway flow and CO~2~ signals were monitored by mainstream sensors placed between the endotracheal tube and the 'Y' piece of the ventilator circuit. Dead space was computed as PCO~2~et--PeCO~2~/PCO~2~et, where PCO~2~et represents the end-tidal partial pressure of CO~2~ and PeCO~2~ the mixed expired CO~2~. Dead space fraction was measured in the first pig by the Bohr equation, with a resulting fraction of 0.85. This dead space fraction was subsequently maintained for the entire duration of the experimental period.

Five experiments were performed in each pig in a standardized fashion. First, ECCO~2~R was performed via a 14.5Fr hemodialysis catheter inserted into the right jugular vein (experiments 1 and 2). Subsequently, ECCO~2~R was performed via the 19Fr catheter following re-catheterization of the same right jugular vein (experiments 3, 4, and 5). Correct placement of the 19Fr cannula was confirmed by echocardiography. Equal conditions were used across all experiments (lasting at least 60 minutes), with each experiment starting at the pre-determined acidotic conditions.

During experiments 1 to 4, blood flow rates were increased in a stepwise fashion, while sweep gas flow was maintained (Table [1](#T1){ref-type="table"}). Each step lasted 15 minutes in order to achieve equilibrium conditions, with all measurements taken at the end of this 15-minute period.

###### 

Experimental set-up (experiments 1 to 5)

  **Parameter**                 **Experiment**   **Experiment**   **Experiment**   **Experiment**   **Experiment**
  ---------------------------- ---------------- ---------------- ---------------- ---------------- ----------------
  **Catheter size** (French)         14.5             14.5              19               19               19
  **Sweep gas flow** (L/min)          8                16               8                16            2 to 10
  **Blood flow** (ml/min)             0                0                0                0              1,000
                                     200              200              250              250                
                                     400              400              500              500                
                                                                       750              750                
                                                                      1,000            1,000               

During experiment 5, sweep gas flow was changed by increasing flow in a stepwise approach (Table [1](#T1){ref-type="table"}), while blood flow was maintained at a rate of 1,000 ml/min. Each step lasted 15 minutes in order to achieve equilibrium conditions.

CO~2~ and blood gas measurement
-------------------------------

CO~2~ was measured in the mainstream of the exhaust/sweep-gas outlet of the oxygenator by the Vaisala Carbocap GM 70 (Vaisala, Bonn, Germany). A water trap was integrated into the circuit before CO~2~ measurement. CO~2~ removal was calculated by multiplying the sweep gas flow with CO~2~ in Vol% in the exhaust/sweep-gas outlet. CO~2~ was measured with 0.04 Vol% in fresh air. Blood gas analysis was performed with an ABL 800, Radiometer, (Copenhagen, Denmark).

Statistics
----------

For statistical analysis, GraphPad Prism 5 for Macintosh computer (La Jolla, CA USA) was used. Data were tested for normality using the Kolmogorov-Smirnov test with a cut-off *P* value of \<0.05. Normally-distributed data are expressed as mean and standard deviation.

Results
=======

ECCO~2~R was most effective with the 19Fr catheter at higher blood flow levels (experiments 3 and 4; Figure [1](#F1){ref-type="fig"}), with no clear difference between different sweep gas flow (8 versus 16 L/minute) conditions. In contrast, ECCO~2~R was less efficient with the 14.5Fr catheter (experiments 1 and 2; Figure [1](#F1){ref-type="fig"}). As a consequence, partial pressure of CO~2~ in arterial blood (PaCO~2~) progressively decreased with increasing blood flow when the 19Fr catheter, but not the 14.5Fr catheter, was used (Figure [2](#F2){ref-type="fig"}). Similarly, pH values progressively increased in proportion with blood flow with the 19Fr catheter, but not the 14.5Fr catheter (Figure [3](#F3){ref-type="fig"}). Of note, non-acidotic blood gas values were only achieved with 19Fr catheters at blood flow rates ranging from 750 to 1,000 ml/minute. Detailed data on CO~2~ elimination and related blood gas values relative to different blood flow levels at a sweep gas flow of 16 L/minute are provided in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}, respectively. The absolute values of CO~2~ elimination were normalized to the partial pressure of CO~2~ in venous blood (PvCO~2~) and a partial pressure of CO~2~ (PCO~2~) value of 45 mmHg according to Wearden *et al*. \[[@B20]\] and are provided in Figure [4](#F4){ref-type="fig"}.

![**Elimination of carbon dioxide (CO**~**2**~**) depending on blood flow. A)** 14.5Fr catheter; 8 L/minute sweep gas flow. **B)** 14.5Fr catheter; 16 L/minute sweep gas flow. **C)** 19Fr catheter; 8 L/minute sweep gas flow. **D)** 19Fr catheter; 16 L/minute sweep gas flow. Fr, French.](cc13928-1){#F1}

![**Partial pressure of arterial carbon dioxide (PaCO**~**2**~**) depending on blood flow. A)** 14.5Fr catheter; 8 L/minute sweep gas flow. **B)** 14.5Fr catheter; 16 L/minute sweep gas flow. **C)** 19Fr catheter; 8 L/minute sweep gas flow. **D)** 19Fr catheter; 16 L/minute sweep gas flow. Fr, French.](cc13928-2){#F2}

![**pH dependence on blood flow. A)** 14.5Fr catheter; 8 L/minute sweep gas flow. **B)** 14.5Fr catheter; 16 L/minute sweep gas flow. **C)** 19Fr catheter; 8 L/minute sweep gas flow. **D)** 19Fr catheter; 16 L/minute sweep gas flow. Fr, French.](cc13928-3){#F3}

###### 

14.5Fr hemodialysis catheter, sweep gas flow 16 L/minute

   **Blood flow \[ml/min\]**   **CO**~**2**~**elimination \[ml/min\]**   **PaCO**~**2**~**\[mmHg\]**     **pH**      **PaO**~**2**~**\[mmHg\]**
  --------------------------- ----------------------------------------- ----------------------------- ------------- ----------------------------
             **0**                                0                              91.3 ± 11.6           7.16 ± 0.07          137.1 ± 26.8
            **200**                          62.4 ± 12.2                         85.6 ± 12.0           7.20 ± 0.06          167.6 ± 27.4
            **400**                          77.9 ± 17.4                         82.3 ± 15.0           7.22 ± 0.07          173.3 ± 21.6

Fr, French; PaCO~2~, partial pressure of CO~2~ in arterial blood; PaO~2~, partial pressure of O~2~ in the arterial blood.

###### 

19Fr Bicaval Dual Lumen Catheter, sweep gas flow 16 L/minute

   **Blood flow \[ml/min\]**   **CO**~**2**~**elimination \[ml/min\]**   **PaCO**~**2**~**\[mmHg\]**     **pH**      **PaO**~**2**~**\[mmHg\]**
  --------------------------- ----------------------------------------- ----------------------------- ------------- ----------------------------
             **0**                                0                             107.9 ± 20.7           7.13 ± 0.08          122.9 ± 29.4
            **250**                          83.4 ± 11.8                         90.3 ± 13.5           7.20 ± 0.06          142.8 ± 35.8
            **500**                         118.7 ± 23.9                         76.9 ± 9.6            7.27 ± 0.06          165.3 ± 39.8
            **750**                         138.3 ± 22.8                         66.9 ± 11.1           7.34 ± 0.09          182.0 ± 42.6
           **1,000**                        146.1 ± 22.6                         55.7 ± 10.5           7.41 ± 0.07          193.6 ± 41.0

![**Normalized elimination of carbon dioxide (CO**~**2**~**) depending on blood flow. A)** 14.5Fr catheter; 8 L/minute sweep gas flow. **B)** 14.5Fr catheter; 16 L/minute sweep gas flow. **C)** 19Fr catheter; 8 L/minute sweep gas flow. **D)** 19Fr catheter; 16 L/minute sweep gas flow.](cc13928-4){#F4}

Corresponding data for different sweep gas flows were comparable, where a higher sweep gas flow of 16 L/minute resulted in only a slightly more effective ECCO~2~R compared to a lower sweep gas flow of 8 L/minute (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}). However, a sweep gas flow below 6 L/minute resulted in less effective ECCO~2~R when large (19Fr) catheters were used at high blood flow levels (1,000 ml/minute) (Figure [5](#F5){ref-type="fig"}). The extracorporeal system was more effective with higher PvCO~2~ and lower blood flow levels and a longer oxygenator contact time, as demonstrated by a lower PCO~2~ post-oxygenator (Figure [6](#F6){ref-type="fig"}).

![**Elimination of carbon dioxide (CO**~**2**~**) in dependence of sweep gas flow under a fixed flood flow of 1,000 ml/minute using a 19Fr catheter. Fr, French.**](cc13928-5){#F5}

![**Partial pressure of arterial (PaCO**~**2**~**) and venous (PvCO**~**2**~**) carbon dioxide depending on blood flow, sweep gas flow and cannula size. A)** 14.5Fr catheter; 8 L/minute sweep gas flow. **B)** 14.5Fr catheter; 16 L/minute sweep gas flow. **C)** 19Fr catheter; 8 L/minute sweep gas flow. **D)** 19Fr catheter; 16 L/minute sweep gas flow. Fr, French.](cc13928-6){#F6}

In three pigs, the sweep gas flow was switched from 100% oxygen to room air at the end of experiment 5, with blood flow rates of 1,000 ml/minute. This resulted in a further increase in CO~2~ removal (150 ± 26.6 versus 159.8 ± 22.6 ml/minute).

Discussion
==========

The present porcine study indicates that pump-driven veno-venous ECCO~2~R can normalize pH values and reduce PaCO~2~ in severe, life-threatening respiratory acidosis under constant ventilatory support. In addition, the present study suggests that a blood flow of 750 to 1,000 ml/minute is needed to achieve these results, since pH values remained acidotic at lower blood flow rates.

In particular, the severe respiratory acidosis in the model used in this study could not be sufficiently corrected either by ECCO~2~R at a blood flow of 200 to 400 ml/minute using the 14.5Fr catheter, or with blood flow rates of 500 ml/minute using the 19Fr cannula. In contrast, severe respiratory acidosis was normalized by veno-venous ECCO~2~R using the 19Fr catheter and a blood flow rate of 1,000 ml/minute, even though a blood flow of 750 ml/minute was sufficient in 50% of the animals. This finding contrasts with a recent study in human patients, where the application of a pump-driven veno-venous system using a 15.5Fr dual-lumen catheter was successful with a mean blood flow of 431 ml/minute \[[@B17]\]. Importantly, however, the mean pH in that study was around 7.25, thus considerably higher compared to the pH in the present study. Thus, based on the current findings, it remains questionable whether more acidotic pH values could also be successfully corrected by lower blood flow rates, although the 15.5Fr catheter has a more favorable design compared to the 14.5Fr Shaldon catheter. Therefore, using low-diameter catheters and low blood flow rates, pump-driven veno-venous ECCO~2~R may be primarily feasible in patients with mild to moderate respiratory acidosis. This may be aimed at reducing aggressiveness of invasive ventilation as originally, and also recently, described in patients with ARDS \[[@B7],[@B9],[@B12],[@B21],[@B22]\].

Interestingly, the ECCO~2~R capacity of the system used in the present study was in line with previous findings that were also derived from an animal study, where a removal-capacity up to 150 ml CO~2~/minute could be achieved with a blood flow of 1,000 ml/minute and an 18Fr catheter \[[@B23]\]. In accordance with the present trial, lower blood flow rates resulted in less efficient ECCO~2~R. In clear contrast, however, the mentioned trial provided evidence that ventilation parameters could be reduced following ECCO~2~R, but again, animals were not as severely acidotic as those in the present study. Therefore, the current study provides the first evidence that even severe acidosis can be successfully managed by ECCO~2~R and, in agreement with our clinical experience, this was only feasible with catheters that allowed blood flow rates of 750 to 1,000 ml/minute.

Since intensive care specialists are familiar with 14.5Fr hemodialysis catheters, it would be reasonable to test whether these catheters also qualify for ECCO~2~R. However, the maximal blood flow through these catheters is physiologically restricted to approximately 400 ml/minute. Furthermore, catheters specifically designed for ECCO~2~R aim to avoid recirculation \[[@B24],[@B25]\]; this is particularly evident if the PCO~2~ of the venous blood, which is directed towards the oxygenator, is lower than arterial PCO~2~. Of note, recirculation was obvious when hemodialysis catheters were used, even with the lowest blood flow rates, demonstrated by a much lower CO~2~ before oxygenator than in the arterial blood (Figure [6](#F6){ref-type="fig"}A and B). In contrast, the specifically designed 19Fr catheter produced no significant recirculation, represented by higher CO~2~ before oxygenator than in arterial blood (Figure [6](#F6){ref-type="fig"}C and D). Therefore, (1) blood flow rates and (2) the specific technical design of the catheter that prevents recirculation are the main determinants of successful ECCO~2~R. Furthermore, CO~2~ elimination of the oxygenator depends closely on the diffusion gradient of CO~2~ between venous blood and the sweep gas. Therefore, with a higher CO~2~ content in venous blood, more CO~2~ will be eliminated, which has to be taken into consideration at the beginning of the experiments, when PvCO~2~ is highest. Furthermore, PaCO~2~ and PvCO~2~ were slightly higher in the low-flow group with the 19Fr than with the 14.5Fr catheter.

In the 1970's, Kolobow \[[@B26]\] and Gattinoni \[[@B27]\] indicated that ECCO~2~R is dependent not only on venous PCO~2~, blood flow and sweep gas flow, but also on the size of the oxygenator. The currently used oxygenator provides a surface area of 0.98 m^2^ without heat exchange fibers. The high efficiency of the system is reflected by a very low mean PaCO~2~ value, leading to alkalotic pH values in the blood that is delivered by the oxygenator at low blood flow rates. This may explain why the previously described linear relationship between sweep gas flow and ECCO~2~R was not observed \[[@B22],[@B24],[@B28]\]. As shown by the present study, sweep gas flow rates of more than 6 L/minute, but not lower flow rates, can sufficiently maintain an optimal ECCO~2~R when a blood flow rate of 1,000 ml/minute is applied.

Interestingly, ECCO~2~R tended to be more efficient when 100% oxygen was switched to room air sweep gas. As hypercapnic respiratory failure is not necessarily associated with severe hypoxemia, the use of air as a sweep gas may slightly improve the effectiveness of ECCO~2~R, but will also reduce the oxygen transfer capacity of the extracorporeal support. On the other hand, the application of oxygen sweep gas was sufficient to improve oxygenation when the ratio of catheter blood flow rate to cardiac output was relatively high, in line with previous results \[[@B24]\].

The current study has some limitations. First, data acquired in animals cannot automatically be transferred into a clinical setting; however, the animals showed CO~2~ production and cardiac output rates that were similar to those observed in adult humans. Previous studies in humans have already shown the clinical effects of ECCO~2~R; thus, the present data are likely to be helpful in understanding the physiology of ECCO~2~R in humans as well. Furthermore, the anatomy of the pig is not comparable to a human adult, and the catheters we used may not be ideal in clinical practice. However, the perfect cannula for CO~2~ removal still has to be designed. Second, the typical clinical scenario of exacerbated COPD with severe airflow limitation was not simulated, since a rather high dead space ventilation protocol was used to artificially increase PaCO~2~. Therefore, the interaction between ECCO~2~R and mechanical ventilation could not be investigated. This, however, is suggested to be of clinical importance, since severe airflow limitation frequently requires the adaptation of ventilator settings. This, in turn, can lead to reduced alveolar ventilation that potentially impacts on acidosis. Third, the present study only applied short-term ECCO~2~R. In a real-life setting, the long-term effects of blood flow, cannula size and sweep gas flow application need to be elucidated, since CO~2~ is also stored in the form of HCO~3~ in slow compartments, and it may take several hours until a steady-state is reached. This is particularly pertinent to patients with acute-on-chronic ventilatory failure who present with respiratory acidosis, hypercapnia and high bicarbonate levels. On the other hand, the time constant for reducing blood CO~2~ in patients by ventilation is 10 minutes \[[@B29]\]; therefore, 15 minutes at each setting should have been an adequate amount of time to detect any changes in PaCO~2~. Furthermore, in the present study we did not put the focus on anticoagulation since clotting was no issue in our short-term experiments of 12 hours duration. Further studies have to be done in humans, since low-flow devices may need more anticoagulation in comparison to high-flow extracorporeal membrane oxygenation (ECMO). Finally, only one system for ECCO~2~R was tested in the present study, and this is suggested to limit the comparison of the current trial with other trials, in which different systems have been used. Nevertheless, the currently used system has shown to be highly effective for ECCO~2~R represented by a PCO~2~ lower than 10 mmHg and a PO~2~ of 600 mmHg after the oxygenator with low blood flows. Although other systems function in a different way, it is physically difficult to further lower PCO~2~. Thus, we believe that the present study is valid to systematically show changes in physiology during ECCO~2~R when using different conditions.

Conclusions
===========

In conclusion, this animal study has shown that severe respiratory acidosis can be successfully managed by veno-venous ECCO~2~R, but only when blood flow rates ranging between 750 and 1,000 ml/minute are applied. For this purpose, the use of specifically-designed catheters with an inner diameter greater than that of the typical hemodialysis catheters are required to establish flow rates ranging between 750 and 1,000 ml/minute and to avoid blood recirculation. In addition, the study has shown that a sweep gas flow rate above 6 L/minute is of minor importance for ECCO~2~R when using modern, highly-efficient oxygenators with low blood-flow rates. This holds true for the system tested, which is highly effective, represented by a PvCO~2~ of 10 to 30 mmHg after the oxygenator and, therefore, may be translated to comparable systems. This study also suggests that low-flow veno-venous ECCO~2~R with modern miniaturized membrane lungs can serve as a treatment option for severe respiratory acidosis associated with acute respiratory failure and severe hypercapnia. Whether these techniques prove to be suitable to avoid endotracheal intubation or to facilitate early extubation in intubated patients needs to be elucidated by future clinical trials.

Key messages
============

• Severe respiratory acidosis with pH values of 7.0 to 7.2 can be successfully managed by veno-venous ECCO~2~R.

• For this purpose, blood flow rates ranging between 750 and 1,000 ml/minute are mandatory.

• Specifically-designed catheters aimed at avoiding blood recirculation warranting the target blood flow are required.

• Sweep gas flow rates above 6 L/minute are sufficient for maximal ECCO~2~R.

Abbreviations
=============

ARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; ECCO~2~R: extracorporeal CO~2~ removal; ECMO: extracorporeal membrane oxygenation; Fr: French; PaCO~2~: partial pressure of CO~2~ in arterial blood; PALP: pump assisted lung protection; PCO~2~: partial pressure of CO~2~; PEEP: positive end expiratory pressure; PVCO~2~: partial pressure of CO~2~ in venous blood; NIV: non-invasive ventilation.
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###### Additional file 1

**Absolute values of CO**~**2**~**elimination and blood gas analysis with a sweep gas flow of 8 L O**~**2**~**/minute depending on blood flow.** The table shows the CO~2~ elimination capacity of the ECCO~2~R system and the corresponding blood gas analysis with a sweep gas flow of 8 L O~2~/minute with a hemodialysis catheter **(A)** and the 19Fr Bicaval Dual Lumen Catheter **(B)** according to different blood flow levels. It is clearly shown that ECCO~2~R is less efficient with the 14.5Fr catheter **(A)** compared to the 19Fr Bicaval Dual Lumen Catheter **(B)**.
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